C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26

Traders Union
All News
Companies
C4 Therapeutics, Inc. unveils trial update

Top Stories

Editors' Picks

Crypto News

Financial News

Currencies

Market Voices

Billionaires

Companies

Regulators News

28.05.2026

C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26 — C4 Therapeutics, Inc. unveils trial update

C4 Therapeutics, Inc. announced plans to present a Trial in Progress poster at ASCO26, focusing on its Phase 2 MOMENTUM clinical trial of cemsidomide.

The therapy is a potential best-in-class IKZF1/3 degrader designed for the treatment of patients with relapsed or refractory multiple myeloma. The presentation will highlight the ongoing research and development efforts to address significant unmet needs in the treatment of this challenging hematologic malignancy.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

C4 Therapeutics previously reported additional Phase 1 data on cemsidomide for refractory multiple myeloma at the EHA 2026 Congress. The company has identified patient-driven clinical research as a key driver in developing targeted protein degradation therapies, according to an earlier update. These efforts reflect an ongoing commitment to advancing new treatment options in hematology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

How precious-metals mining revival is reshaping portfolios in 2026

By Ciaran Ryan
16 hours ago

How precious-metals mining revival is reshaping portfolios in 2026

Editors' Picks

Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?

By Mikhail Vnuchkov
20 hours ago

Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?

Editors' Picks

Five years with Bitcoin: How El Salvador changed after legalizing BTC

By Eugene Komchuk
Yesterday

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Editors' Picks

All Editors' Top Picks

Latest C4 Therapeutics News

C4 Therapeutics presents data on cemsidomide plus dexamethasone trial at EHA2026

By Elena Nikulina
16 hours ago

C4 Therapeutics presents data on cemsidomide plus dexamethasone trial at EHA2026

Companies

#C4 Therapeutics

Executive team at C4 Therapeutics, Inc. set for Jefferies conference fireside chat

By Anastasiia Chabaniuk
03.06.2026

Executive team at C4 Therapeutics, Inc. set for Jefferies conference fireside chat

Companies

#C4 Therapeutics

Clinical trial participation drives development of innovative treatments, C4 Therapeutics, Inc.

By Igor Krasulya
20.05.2026

Clinical trial participation drives development of innovative treatments, C4 Therapeutics, Inc.

Companies

#C4 Therapeutics

All C4 Therapeutics News

Ciaran Ryan
16 hours ago

How precious-metals mining revival is reshaping portfolios in 2026

Mikhail Vnuchkov
20 hours ago

Bitcoin price prediction after CPI rise: Is BTC headed for deeper losses?

Eugene Komchuk
Yesterday

Five years with Bitcoin: How El Salvador changed after legalizing BTC

Anastasiia Chabaniuk
09.06.2026

Crypto on the court: How NBA Finals became a showcase for Ledger

Johnathan Maverick
08.06.2026

How to build wealth from scratch in 3 practical steps

Artem Shendetskii
11 min ago

Tren Griffin: SpaceX sets IPO price at $135 a share, aiming to raise $75 billion

Jose Antonio Gastelum
16 min ago

Sui DeFi to enable 24/7 Asian equity trading, Adeniyi Abiodun notes

Daria Chernytska
31 min ago

Ethereum will not reach zero today, Wendy O notes

Ivan Andriyenko
1 hour ago

Lennar average selling price falls 24.4% since 2022 peak, Lance Lambert notes

Yaroslav Dmytrenko
1 hour ago

Michael A. Gayed: Bitcoin holding compared to selling a kidney

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Ivan Andriyenko
14 hours ago

U.S. gas exports gain ground in India as Gulf supplies falter

U.S. gas exports gain ground in India as Gulf supplies falter

Parshwa Turakhiya
16 hours ago

Japan crypto bill moves closer to final passage

Japan crypto bill moves closer to final passage

Igor Krasulya
17 hours ago

Inflation pressure pushes ECB toward rate hike

Inflation pressure pushes ECB toward rate hike

Eugene Komchuk
17 hours ago

Police investigate Bithumb chief over hiring of lawmaker's son

Police investigate Bithumb chief over hiring of lawmaker's son

Andrey Mastykin
19 hours ago

U.S. strikes on Iran send Wall Street futures higher

U.S. strikes on Iran send Wall Street futures higher

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Google doubles down on AI amid stock pressure and regulatory risks

Anton Kharitonov
Now

Microsoft breaks support as pressure on shares intensifies

Mykhailo Ihnatenko
Now

Silver rebounds as Middle East tensions revive safe-haven demand

Anton Kharitonov
Now

Apple remains under pressure despite strong fundamentals

Mykhailo Ihnatenko
Now

AI stocks face first major liquidity test

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.